How Can We Unlock the Next Wave of GPCR Therapeutics?
As the industry looks beyond GLP-1 therapeutics to identify the next breakthrough opportunity, researchers are accelerating the discovery of novel GPCR targets through advances in AI-enabled drug discovery, GPCR structural biology, cryo-EM, structure-guided drug design, next-generation screening technologies, and GPCR signaling biology. Yet significant challenges remain, from advancing orphan GPCR drug discovery and GPCR target validation to translating complex receptor biology into first-in-class and best-in-class therapeutics.
-
Unlock novel GPCR biology through advances in orphan GPCRs, deorphanization, receptor biology, target validation, and the identification of emerging GPCR targets.
-
Accelerate GPCR-targeted drug discovery with AI for GPCR drug discovery, machine learning approaches, structure-based drug design (SBDD), advanced screening platforms, DNA-encoded library screening, and translational pharmacology strategies.
-
Explore next-generation GPCR therapeutics across small molecules, antibodies, biologics, peptides, ADCs, and multi-receptor therapeutics targeting obesity, oncology, CNS, immunology, autoimmune diseases, inflammation, and pain.
What To Expect?
Go Beyond GLP-1 to Identify the Next GPCR Breakthrough
Discover where the industry's next major scientific and commercial opportunities are emerging across novel targets, transformative technologies, and next-generation therapeutics.
Featuring Insights from:
Evaluate What AI & ML Has Actually Delivered for GPCR Discovery
Move beyond AI hype and benchmark how leading organizations are leveraging machine learning and computational approaches to improve discovery outcomes, candidate quality, and decision-making.
Featuring insights from:
Unlock the Next Generation of GPCR Targets
Explore emerging approaches to orphan receptor discovery, target validation, super-dark GPCR biology, and signaling science to expand the future landscape of druggable receptors.
Featuring insights from:
Advance Emerging Modalities Beyond Traditional Small Molecules
Compare the latest progress in antibodies, peptides, biologics, and multi-receptor therapeutics to determine the optimal modality for future GPCR programs.
Featuring insights from:
Attending Companies Include